IGL Group has acquired Celsior®
The IGL Group, based in France, has acquired Celsior® from Sanofi Genzyme for US$11.5 million.
Companies within the IGL Group develop research programmes that have led to the development of products designed specifically to improve organ recovery, preservation, transport and evaluation systems before transplant. The IGL-1® preservation solution is particularly well suited for expanded criteria donors.
Celsior®, producing liquid compositions for perfusion, reperfusion and preservations of organs, is part of the Sanofi Genzyme group, a global healthcare leader focused on the research, development, manufacturing and marketing of innovative therapeutic solutions.
Sanofi Genzyme is engaged in the research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi's core strength is in the healthcare sector, with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Related deals
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreThe Canton of Solothurn had a valuation report prepared for its hospitals
The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.
Learn moreGenerali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
Learn more